PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

A pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease

2024-05-24
(Press-News.org) Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

A pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease.1 The landmark trial, presented today at the 61st ERA Congress, will pave the way for new treatment strategies and offer hope to millions of patients globally.

The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study is a double-blind, randomised, placebo-controlled international trial comprising 3,533 patients, with a median follow-up period of 3.4 years. The trial was designed to assess the efficacy and safety of semaglutide, a once-weekly subcutaneous glucagon-like peptide 1 (GLP-1) receptor agonist, in preventing major kidney outcomes, specifically kidney failure, substantial loss of kidney function, and death from kidney or cardiovascular causes, in individuals with type 2 diabetes and chronic kidney disease. Patients either received semaglutide 1.0 mg once weekly or placebo.

Participants who received semaglutide had a 24% risk reduction for the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes, compared to those who received placebo. This reduction risk was consistent across both kidney-specific and cardiovascular death outcomes.

Secondary endpoints also showed significant improvements with semaglutide. Specifically, the total eGFR slope was 1.16 ml/min/1.73m2/year slower, the risk of major cardiovascular events was decreased by 18%, and the risk of all-cause mortality was reduced by 20%.

This evidence of efficacy, combined with fewer serious adverse events in the semaglutide group, offers hope to millions of patients globally who face the daunting prospect of chronic kidney disease and type 2 diabetes, and their related complications.

Professor Vlado Perkovic, who presented the results for the first time today at the 61st ERA Congress, emphasised the importance of these results, “The use of semaglutide in people with type 2 diabetes and chronic kidney disease can lower the risk of major kidney outcomes and reduce the risk of cardiovascular events, cardiovascular death and all-cause death. These benefits signify a profound clinical impact saving kidneys, hearts and lives, for patients with type 2 diabetes and chronic kidney disease. Additionally, the reassuring safety findings further support the strong potential value of semaglutide in this population.”

Chronic kidney disease affects over 800 million people worldwide and is particularly prevalent among individuals with type 2 diabetes.2 Chronic kidney disease poses a significant risk of kidney failure, cardiovascular events and death,3 highlighting the critical need for research into its prevention and treatment. While current therapies have demonstrated kidney protection and reduced cardiovascular risks, many individuals continue to experience declining kidney function and adverse outcomes. This has sparked a growing interest in exploring new treatments, including GLP-1 receptor agonists.1

Professor Vlado Perkovic further states, “These findings offer great promise in reshaping treatment strategies for individuals at high risk of diabetes-related complications, offering a new avenue for kidney and cardiovascular protection.”

The FLOW trial was overseen by an academic-led Steering Committee, in partnership with the study sponsor, Novo Nordisk, which also managed trial operations. The study is being published today in the New England Journal of Medicine and presented at the 61st ERA Congress in Stockholm, Sweden.

 

ENDS

 

Notes to editors:

A reference to the ERA Congress must be included in all coverage and/or articles associated with this study.

For more information or to arrange an expert interview, please contact press@era-online.org

 

About the study author:

Professor Vlado Perkovic is Dean of Medicine and Health and Scientia Professor at UNSW Sydney, a Professorial Fellow at The George Institute, Australia, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular in preventing the progression of kidney disease and its complications. He has led several major international clinical trials that have identified new treatments to prevent kidney failure.

 

About the European Renal Association (ERA):

With more than 25,000 active members, the ERA is one of the biggest nephrology associations worldwide leading European nephrology, and one of the most important European Medical Associations. It organises annual congresses and other educational and scientific activities. The ERA also collects data and performs epidemiological studies through its Registry. The Society supports fellowships and educational/research projects through its committees and working groups. Its publications are NDT, CKJ (Open Access journal), and the online educational portal NEP.

The 61st ERA Congress takes place between 23-26 May 2024, both virtually and live in Stockholm, Sweden.

Website: www.era-online.org

 

References:

Effects of Semaglutide on Chronic Kidney Disease in Type 2 Diabetes, Perkovic V. et al. (2024). Presented at the ERA Congress 2024. Kovesdy C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements, 12(1), 7–11. https://doi.org/10.1016/j.kisu.2021.11.003 Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021). Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, obesity & metabolism, 23(9), 2058–2066. https://doi.org/10.1111/dom.14443 Rossing P et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 Aug 31;38(9):2041-2051. doi: 10.1093/ndt/gfad009. Erratum in: Nephrol Dial Transplant. 2024 Mar 27;39(4):724. PMID: 36651820; PMCID: PMC10469096. END



ELSE PRESS RELEASES FROM THIS DATE:

Unveiling a novel AAK1 inhibitor: How chemical proteomics unlocked therapeutic potential

Unveiling a novel AAK1 inhibitor: How chemical proteomics unlocked therapeutic potential
2024-05-24
Enhancing drug development for life-threatening diseases like cancer hinges on a deep understanding of protein kinases, making it a focal point for researchers. These enzymes, encoded by more than 500 human genes, serve as critical players in cellular signaling pathways. However, if these signals are dysregulated, they can disrupt the normal cellular mechanisms, leading to diseases such as cancer. Protein kinase inhibitors have therefore provided a promising avenue in therapeutic intervention to disrupt the aberrant signaling ...

Novel organic photoredox catalysts with enhanced stability and recyclability

Novel organic photoredox catalysts with enhanced stability and recyclability
2024-05-24
In recent years, global environmental concerns have prompted a shift toward eco-friendly manufacturing in the field of organic synthetic chemistry. In this regard, research into photoredox catalytic reactions, which use light to initiate redox or reduction-oxidation reactions via a photoredox catalyst, has gained significant attention. This approach reduces the reliance on harsh and toxic reagents and uses visible light, a clean energy source. A key research area has been the development of recycling methods for photocatalysts, which offer both economic and environmental benefits. Photocatalysts use light to accelerate a chemical reaction without getting consumed in the process, and photoredox ...

Imperceptible sensors made from ‘electronic spider silk’ can be printed directly on human skin

Imperceptible sensors made from ‘electronic spider silk’ can be printed directly on human skin
2024-05-24
Researchers have developed a method to make adaptive and eco-friendly sensors that can be directly and imperceptibly printed onto a wide range of biological surfaces, whether that’s a finger or a flower petal. The method, developed by researchers from the University of Cambridge, takes its inspiration from spider silk, which can conform and stick to a range of surfaces. These ‘spider silks’ also incorporate bioelectronics, so that different sensing capabilities can be added to the ‘web’. The fibres, at least 50 times smaller than a ...

Virginia Tech researcher’s breakthrough discovery uses engineered surfaces to shed heat

Virginia Tech researcher’s breakthrough discovery uses engineered surfaces to shed heat
2024-05-24
Splash a few drops of water on a hot pan and if the pan is hot enough, the water will sizzle and the droplets of water seem to roll and float, hovering above the surface. The temperature at which this phenomenon, called the Leidenfrost effect, occurs is predictable, usually happening above 230 degrees Celsius. The team of Jiangtao Cheng, associate professor in the Virginia Tech Department of Mechanical Engineering, has discovered a method to create the aquatic levitation at a much lower temperature, and the results have been published in Nature ...

How a tiny device could lead to big physics discoveries and better lasers

How a tiny device could lead to big physics discoveries and better lasers
2024-05-24
Researchers at Rensselaer Polytechnic Institute have fabricated a device no wider than a human hair that will help physicists investigate the fundamental nature of matter and light. Their findings, published in the journal Nature Nanotechnology, could also support the development of more efficient lasers, which are used in fields ranging from medicine to manufacturing. The device is made of a special kind of material called a photonic topological insulator. A photonic topological insulator can guide photons, the wave-like particles that make up light, ...

Ambitious targets are needed to end ocean plastic pollution by 2100

2024-05-24
The study, a collaboration between researchers at Imperial College London and GNS Science, suggests that reducing plastic pollution by 5% per year would stabilize the level of microplastics – plastics less than 5 mm in length – in the surface oceans. However, the modelling shows that even reducing pollution by 20% per year would not significantly reduce existing microplastics levels, meaning they will persist in our oceans beyond 2100. Microplastics have been found to be circulating in all of the Earth’s oceans and some of the greatest concentrations of them are thousands of miles from land. These tiny particles ...

Boost for research aiming to cure chronic diseases in an aging population

Boost for research aiming to cure chronic diseases in an aging population
2024-05-24
The DRIVE-RM consortium, led by Professor of Experimental Nephrology Marianne Verhaar from UMC Utrecht, has been awarded €37.5 million under the prestigious NWO SUMMIT program. The SUMMIT grant recognizes world-class collaborations, while further strengthening these partnerships. The DRIVE-RM collaboration involves UMC Utrecht, Utrecht University, Eindhoven University of Technology, Maastricht University, and the Hubrecht Institute, focusing on smart materials that assist the body in healing. Regenerative medicine involves repairing or replacing damaged tissues and organs by leveraging the body's own healing processes. DRIVE-RM ...

Quadruple therapies and the future of multiple myeloma treatment

Quadruple therapies and the future of multiple myeloma treatment
2024-05-24
MIAMI, FLORIDA (MAY 23, 2024) – The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent. Over the last decade, options have evolved from double, to triple to quadruple combination therapies. What do these new options mean for patients, and how will treatment change in the future? C. Ola Landgren, M.D., Ph.D., will ...

Announcement of winners for the third “Marie Sklodowska Curie Award”

Announcement of winners for the third “Marie Sklodowska Curie Award”
2024-05-24
JST has selected winners for the third Marie Sklodowska Curie Award for young female researchers. For the third Marie Sklodowska Curie Award, we accepted applications from October 2 to December 11, 2023. Through document screenings and interviews with external experts, we have selected one Grand Prize winner and two Inspiration Prize winners. JEOL Ltd. will award 1M yen for the Grand Prize and 500K yen for each Inspiration Prize. JST recognizes the importance of initiatives designed to promote the activities of female researchers in science, technology, and innovation, and based on this belief we established the “Marie ...

Baby bonuses and wedding bells: how life's big moments can challenge startups

2024-05-24
Life-changing events like the birth of a child, the purchase of a new home, or a lottery win could threaten the survival of a new business venture, research from Edith Cowan University (ECU) has found. A recent study led by ECU’s Professor of Entrepreneurship and Innovation Pi-Shen Seet with Associate Professor Wee-Liang Tan from the Singapore Management University found that positive family events had a comparatively greater influence, albeit negatively, on the survival of a new venture, compared with negative events. “A positive family event, like the birth of a child, often has an emotional spin-on effect for an entrepreneur ...

LAST 30 PRESS RELEASES:

Inability to pay for healthcare reaches record high in U.S.

Science ‘storytelling’ urgently needed amid climate and biodiversity crisis

KAIST Develops Retinal Therapy to Restore Lost Vision​

Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response

Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid

Low LDL cholesterol levels linked to reduced risk of dementia

Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients

Almost one in ten people surveyed report having been harmed by the NHS in the last three years

Enhancing light control with complex frequency excitations

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

New insight into factors associated with a common disease among dogs and humans

Illuminating single atoms for sustainable propylene production

New study finds Rocky Mountain snow contamination

Study examines lactation in critically ill patients

UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award

Doubling down on metasurfaces

New Cedars-Sinai study shows how specialized diet can improve gut disorders

Making moves and hitting the breaks: Owl journeys surprise researchers in western Montana

PKU Scientists simulate the origin and evolution of the North Atlantic Oscillation

ICRAFT breakthrough: Unlocking A20’s dual role in cancer immunotherapy

How VR technology is changing the game for Alzheimer’s disease

A borrowed bacterial gene allowed some marine diatoms to live on a seaweed diet

Balance between two competing nerve proteins deters symptoms of autism in mice

Use of antifungals in agriculture may increase resistance in an infectious yeast

Awareness grows of cancer risk from alcohol consumption, survey finds

The experts that can outsmart optical illusions

Pregnancy may reduce long COVID risk

Scientists uncover novel immune mechanism in wheat tandem kinase

Three University of Virginia Engineering faculty elected as AAAS Fellows

Unintentional drug overdoses take a toll across the U.S. unequally, study finds

[Press-News.org] Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals
A pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease